Question 1

How do β-blockers work to inhibit sympathetic responses?

Accepted Answer

β-blockers bind competitively to β receptors and inhibit catecholamine-mediated sympathetic responses. All β blockers function as competitive antagonists, but they differ in characteristics such as adrenoceptor subtype affinity, lipophilicity, and α-blockade ability. This mechanism makes them effective in modulating the sympathetic nervous system.

Question 2

What distinguishes selective β1-blockers from nonselective β-blockers?

Accepted Answer

Selective β1-blockers like atenolol and metoprolol target primarily β1 receptors, providing cardioselective actions that benefit heart function. Nonselective β-blockers such as propranolol affect both β1 and β2 receptors. This selectivity allows clinicians to tailor therapy based on therapeutic goals and patient-specific conditions.

Question 3

What was the first β-blocker developed, and how did it differ from propranolol?

Accepted Answer

Dichloroisoprenaline was the prototype β-blocker but exhibited partial agonist activity. Propranolol was subsequently developed as a pure antagonist, though it remained nonselective. This advancement eliminated unwanted agonist effects while establishing the foundation for developing more targeted β-blocking agents with improved selectivity.

Question 4

How are β-blockers classified by generation, and what defines each generation?

Accepted Answer

First-generation β-blockers are older, nonselective molecules like propranolol. Second-generation drugs are cardioselective agents such as atenolol and metoprolol. Third-generation includes newer drugs like labetalol and carvedilol with additional α-blocking or vasodilatory actions, offering expanded therapeutic benefits for diverse patient populations.

Question 5

What additional properties do third-generation β-blockers like carvedilol and labetalol provide?

Accepted Answer

Third-generation β-blockers such as carvedilol and labetalol possess dual α-blocking or vasodilatory properties in addition to β-blockade. These combined actions offer therapeutic advantages in managing hypertension and heart failure by simultaneously targeting both α- and β-adrenergic receptors, providing more comprehensive sympathetic modulation.

Question 6

Why is lipophilicity an important characteristic distinguishing different β-blockers?

Accepted Answer

Lipophilicity affects a β-blocker's ability to cross the blood-brain barrier and penetrate tissues. β-blockers differ in lipophilicity, which influences their distribution, metabolism, and clinical effects. This characteristic, along with adrenoceptor subtype affinity and α-blockade ability, determines how each drug behaves pharmacologically and therapeutically.

Question 7

What clinical conditions benefit from β-blocker therapy?

Accepted Answer

β-blockers are therapeutically important in treating heart ailments and hemodynamic disorders. Their ability to inhibit catecholamine-mediated sympathetic responses makes them valuable for managing conditions like hypertension, heart failure, and arrhythmias. The diversity of β-blocker types allows selection based on specific patient needs and disease characteristics.

Адреноблокаторы: Химия и классификация блокаторы β-рецепторов.